Can you provide the last earnings date for QUINCE THERAPEUTICS INC?
QUINCE THERAPEUTICS INC (QNCX) last reported earnings on 3/23/2026.
NASDAQ:QNCX • US22053A1079
Past quarterly earnings results for QUINCE THERAPEUTICS INC (QNCX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.25 | -0.22 | -13.26% | -92.31% | - | - | ||
| Q2 2025 | -0.23 | -0.26 | 10.40% | - | - | - | ||
| Q1 2025 | -0.34 | -0.23 | -46.52% | -30.77% | - | - | ||
| Q4 2024 | -0.28 | -0.18 | -56.86% | - | - | - | ||
| Q3 2024 | -0.13 | -0.21 | 39.31% | 13.33% | - | - | ||
| Q2 2024 | - | - | - | - | ||||
| Q1 2024 | -0.26 | - | 17.51% | - | - | |||
| Q4 2023 | - | - | - | - | ||||
| Q3 2023 | -0.15 | - | 31.82% | - | - | |||
| Q2 2023 | - | - | - | - | ||||
| Q1 2023 | -0.32 | - | 56.22% | - | - | |||
| Q4 2022 | -0.29 | - | 62.34% | - | - | |||
| Q3 2022 | -0.22 | -0.29 | 24.05% | 69.86% | - | - | ||
| Q2 2022 | -0.51 | -0.49 | -3.09% | 31.08% | - | - | ||
| Q1 2022 | -0.72 | -0.56 | -28.90% | 7.69% | - | - | ||
| Q4 2021 | -0.78 | -0.66 | -17.74% | -13.04% | - | - | ||
| Q3 2021 | -0.73 | -0.76 | 3.76% | - | - | - | ||
| Q2 2021 | -0.74 | -0.77 | 4.29% | -23.33% | - | - | ||
| Q1 2021 | -0.78 | -0.74 | -6.02% | -27.87% | - | - | ||
| Q4 2020 | -0.69 | -0.75 | 7.62% | - | - | - | ||
| Q3 2020 | -0.73 | -0.63 | -16.26% | - | - | - | ||
| Q2 2020 | -0.60 | -0.63 | 4.84% | - | - | - | ||
| Q1 2020 | -0.61 | -0.45 | -36.46% | - | - | - |
Notes
QUINCE THERAPEUTICS INC (QNCX) last reported earnings on 3/23/2026.
QUINCE THERAPEUTICS INC (QNCX) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, QUINCE THERAPEUTICS INC (QNCX) has beaten EPS estimates in 1 out of 4 releases.